The expression profile of ATP-binding cassette transporter genes in breast carcinoma

Pharmacogenomics

Volumn 14, Issue 5, 2013, Pages 515-529

  Hlaváč, Viktor ^a,b   Brynychová, Veronika ^a,b   Václavíková, Radka ^a   Ehrlichová, Marie ^a,b   Vrána, David ^a,f   Pecha, Václav ^c   Koževnikovová, Renata ^c   Trnková, Markéta ^d   Gatěk, Jiří ^e   Kopperová, Dana ^b   Gut, Ivan ^a   Souček, Pavel ^a  

^a NATIONAL INSTITUTE OF PUBLIC HEALTH   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c Medicon ^*  (Czech Republic)

^d Biolab Praha   (Czech Republic)

^e Atlas Hospital   (Czech Republic)

^f PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

ABC transporters; breast carcinoma; expression; prognosis; resistance; response

Indexed keywords

ABC TRANSPORTER; CYCLOPHOSPHAMIDE; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; KI 67 ANTIGEN; PACLITAXEL; PROGESTERONE RECEPTOR;

ABC GENE; ABCA10 GENE; ABCA12 GENE; ABCA13 GENE; ABCA2 GENE; ABCA3 GENE; ABCA5 GENE; ABCA6 GENE; ABCA7 GENE; ABCA8 GENE; ABCA9 GENE; ABCB1 GENE; ABCB10 GENE; ABCB11 GENE; ABCB2 GENE; ABCB3 GENE; ABCB5 GENE; ABCB8 GENE; ABCB9 GENE; ABCC1 GENE; ABCC10 GENE; ABCC11 GENE; ABCC12 GENE; ABCC4 GENE; ABCC5 GENE; ABCC6 GENE; ABCC8 GENE; ABCC9 GENE; ABCD2 GENE; ABCD3 GENE; ABCD4 GENE; ABCE1 GENE; ABCF1 GENE; ABCF2 GENE; ABCF3 GENE; ABCG1 GENE; ABCG5 GENE; ABCG8 GENE; ADULT; ARTICLE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GENE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; NUCLEOTIDE SEQUENCE; PHARMACOGENETICS; PREDICTIVE VALUE; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BREAST NEOPLASMS; CARCINOMA; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC ASSOCIATION STUDIES; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY;

EID: 84875929563     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.13.26     Document Type: Article

References (38)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer. 127, 2893-2917 (2010
2. Coughlin SS, Ekwueme DU. Breast cancer as a global health concern. Cancer Epidemiol. 33, 315-318 (2009
3. Baguley BC. Multiple drug resistance mechanisms in cancer. Mol. Biotechnol. 46, 308-316 (2010
4. Szakacs G, Paterson JK, Ludwig JA, Booth- Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov. 5, 219-234 (2006
5. Klaassen CD, Aleksunes LM. Xenobiotic, bile acid, and cholesterol transporters: function and regulation. Pharmacol. Rev. 62, 1-96 (2010
6. Wolf SJ, Bachtiar M, Wang J, Sim TS, Chong SS, Lee CG. An update on ABCB1 pharmacogenetics: insights from a 3D model into the location and evolutionary conservation of residues corresponding to SNPs associated with drug pharmacokinetics. Pharmacogenomics J. 11, 315-325 (2011
7. Burger H, Foekens JA, Look MP et al. RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response. Clin. Cancer Res. 9, 827-836 (2003 (Pubitemid 36182621)
8. Atalay C, Demirkazik A, Gunduz U. Role of ABCB1 and ABCC1 gene induction on survival in locally advanced breast cancer. J. Chemother. 20, 734-739 (2008
9. Larkin A, O'Driscoll L, Kennedy S et al. Investigation of MRP-1 protein and MDR-1 P-glycoprotein expression in invasive breast cancer: a prognostic study. Int. J. Cancer 112, 286-294 (2004 (Pubitemid 39244369)
10. Moureau-Zabotto L, Ricci S, Lefranc JP et al. Prognostic impact of multidrug resistance gene expression on the management of breast cancer in the context of adjuvant therapy based on a series of 171 patients. Br. J. Cancer 94, 473-480 (2006 (Pubitemid 43289749)
11. Vaclavikova R, Nordgard SH, Alnaes GIG et al. Single nucleotide polymorphisms in the multidrug resistance gene 1 (ABCB1): effects on its expression and clinicopathological characteristics in breast cancer patients. Pharmacogenet. Genomics 18, 263-273 (2008 (Pubitemid 351323241)
12. Rudas M, Filipits M, Taucher S et al. Expression of MRP1, LRP and Pgp in breast carcinoma patients treated with preoperative chemotherapy. Breast Cancer Res. Treat. 81, 149-157 (2003 (Pubitemid 37211132)
13. Natarajan K, Xie Y, Baer MR, Ross DD. Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance. Biochem. Pharmacol. 83, 1084-1103 (2012
14. Park S, Shimizu C, Shimoyama T et al. Gene expression profiling of ATP-binding cassette (ABC) transporters as a predictor of the pathologic response to neoadjuvant chemotherapy in breast cancer patients. Breast Cancer Res. Treat. 99, 9-17 (2006 (Pubitemid 44168598)
15. Vaclavikova R, Ehrlichova M, Hlavata I et al. Detection of frequent ABCB1 polymorphisms by high-resolution melting curve analysis and their effect on breast carcinoma prognosis. Clin. Chem. Lab. Med. 50, 1999-2007 (2012
16. Hubackova M, Vaclavikova R, Ehrlichova M et al. Association of superoxide dismutases and NAD(P)H oxidoreductases with prognosis of patients with breast carcinomas. Int. J. Cancer 130, 338-348 (2012
17. Hammond ME, Hayes DF, Dowsett M et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch. Pathol. Lab. Med. 134, 907-922 (2010
18. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783-792 (2001 (Pubitemid 32222155)
19. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl Cancer Inst. 92, 205-216 (2000
20. Hlavata I, Mohelnikova-Duchonova B, Vaclavikova R et al. The role of ABC transporters in progression and clinical outcome of colorectal cancer. Mutagenesis 27, 187-196 (2012
21. Mohelnikova-Duchonova B, Oliverius M, Honsova E, Soucek P. Evaluation of reference genes and normalization strategy for quantitative real-time PCR in human pancreatic carcinoma. Dis. Markers 32, 203-130 (2012
22. Bustin SA, Benes V, Garson JA et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin. Chem. 55, 611-622 (2009
23. Vobořilova J, Němcova-Fürstova V, Neubauerova J et al. Cell death induced by novel fluorinated taxanes in drug-sensitive and drug-resistant cancer cells. Invest. New Drugs 29(3), 411-423 (2011
24. Honorat M, Mesnier A, Vendrell J et al. ABCC11 expression is regulated by estrogen in MCF7 cells, correlated with estrogen receptor a expression in postmenopausal breast tumors and overexpressed in tamoxifen-resistant breast cancer cells. Endocr. Relat. Cancer 15, 125-138 (2008 (Pubitemid 351449733)
25. Xiang L, Su P, Xia S et al. ABCG2 is associated with HER-2 expression, lymph node metastasis and clinical stage in breast invasive ductal carcinoma. Diagn. Pathol. 6, 90 (2011
26. Bera TK, Lee S, Salvatore G, Lee B, Pastan I. MRP8, a new member of ABC transporter superfamily, identified by EST database mining and gene prediction program, is highly expressed in breast cancer. Mol. Med. 7, 509-516 (2001
27. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer I. The value of histological grade in breast cancer: experience from a large study with long-term follow up. Histopathology 19, 403-410 (1991
28. Fasching PA, Heusinger K, Haberle L et al. Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. BMC Cancer 11, 486 (2011
29. Charpin C, Vielh P, Duffaud F et al. Quantitative immunocytochemical assays of P-glycoprotein in breast carcinomas: correlation to messenger RNA expression and to immunohistochemical prognostic indicators. J. Natl Cancer Inst. 86, 1539-1545 (1994 (Pubitemid 24330219)
30. Rybarova S, Hodorova I, Hajdukova M et al. Expression of MDR proteins in breast cancer and its correlation with some clinical and pathological parameters. Neoplasma 53, 128-135 (2006
31. Zochbauer-Müller S, Filipits M, Rudas M et al. P-glycoprotein and MRP1 expression in axillary lymph node metastases of breast cancer patients. Anticancer Res. 21, 119-124 (2001 (Pubitemid 32267633)
32. McDonagh EM, Whirl-Carrillo M, Garten Y, Altman RB, Klein TE. From pharmacogenomic knowledge acquisition to clinical applications: the PharmGKB as a clinical pharmacogenomic biomarker resource. Biomark. Med. 5, 795-806 (2011
33. Thorn CF, Oshiro C, Marsh S et al. Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenet. Genomics 21, 440-446 (2011
34. Filipits M, Pohl G, Rudas M et al. Clinical role of multidrug resistance protein 1 expression in chemotherapy resistance in early-stage breast cancer: the Austrian Breast and Colorectal Cancer Study Group. J. Clin. Oncol. 23, 1161-1168 (2005 (Pubitemid 46202272)
35. Reams RR, Kalari KR, Wang H, Odedina FT, Soliman KF, Yates C. Detecting gene-gene interactions in prostate disease in African American men. Infect. Agent Cancer 6, S1-S10 (2011
36. Yamamoto-Ibusuki M, Yamamoto Y, Yamamoto S et al. Comparison of prognostic values between combined immunohistochemical score of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, Ki-67 and the corresponding gene expression score in breast cancer. Mod. Pathol. 26, 79-86 (2013
37. The expression profile of ABC transporter genes in post-treatment breast carcinomas. www.ncbi.nlm.nih.gov/geo/query/acc. cgi?acc=GSE43807
38. The Human Protein Atlas. ABCA13. www.proteinatlas.org/ENSG00000179869